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Background {#Sec2}
==========

Eepidemiological status of lymphatic filariasis {#Sec3}
-----------------------------------------------

Historically, lymphatic filariasis (LF) had been endemic only in some parts of Thailand, with both brugian and bancroftian filariasis being reported \[[@CR1]--[@CR5]\]. The first survey for LF was recorded as early as 1949 by the Department of Health, Ministry of Public Health (MoPH) and found that there was lymphatic filariasis, lymphoedema cases in six southern provinces; Chumphon, Surat Thani, Nakhon Si Thammarat, Phatthalung, Pattani and Narathiwat. Between 1951 and 1952 the World Health Organization (WHO) conducted LF blood surveys in four provinces of Surat Thani, Nakhon Si Thammarat, Phatthalung and Pattani, and found microfilarial positive rate averaging 21.0% (2.9--40.8%), all cases were *Brugia malayi* infection. The elephantiasis rate was 5.2%. The vector identified were *Mansonia* spp. (four species) and *Anopheles* spp. (five species) infected with infective stage larvae of *B. malayi*. The disease was recognized as being of public health importance in 1953. Between 1960 and 1961 Faculty of Tropical Medicine, Mahidol University and the Department of Health conducted LF surveys in three districts of Nakhon Si Thammarat province and detected 1246 cases. Between 1961 and 1988 numerous LF surveys were conducted in provinces of Surat Thani, Chumphon, Kanchanaburi and Mae Hong Son. The microfilariae (mf) surveys were then expanded over 1994--1995 to cover 32 provinces. In highly endemic provinces of Narathiwat \> 900 village-surveys (includes first ever survey of hundreds of villages and resurvey of some villages to evaluate the impact of diethylcarbamazine citrate \[DEC\] treatment) were done during 1978--2001 and in Tak province \> 600 village-surveys were performed over 1986--2001. In some provinces, notably Phang Nga where prevalence was confined to only a few villages, repeated treatment with DEC enabled the eventual elimination of LF.

Programme structure in Thailand {#Sec4}
-------------------------------

In the year 1961, the Division of Lymphatic Filariasis was established under the Department of Health, MoPH with a primary strategy of using DEC to control LF in known endemic areas \[[@CR6]\]. The MoPH of Thailand launched the National Programme to Eliminate LF (NPELF) in Thailand in 2001. The NPELF strategies and its objectives are shown in Fig. [1](#Fig1){ref-type="fig"} and initially aimed to cease mass drug administration (MDA) by 2007 \[[@CR7], [@CR8]\]. The structure and organization of the programme is shown in Fig. [2](#Fig2){ref-type="fig"}. The Bureau of Vector-Borne Diseases (BVBD) under the Department of Disease Control (DDC) in the MoPH implements vector control and disease control programmes. Within the BVBD, the Cluster of Lymphatic Filariasis, headed by a programme manager coordinates the implementation of the NPELF.Fig. 1National Programme for Elimination of Lymphatic Filariasis in Thailand: Strategies, objectives and timelinesFig. 2Structure of National Programme for Elimination of Lymphatic Filariasis in Thailand

At the province level, the respective Provincial Health Office (PHO), headed by the provincial chief medical officer coordinates the implementation of the programme, particularly the MDA activities, within the endemic provinces through liaising with DHOs. The provincial Vector Borne Disease Centre (VBDC) plays an important role in the monitoring and evaluation (M&E) and surveillance activities. The District Health Office (DHO) interacts with sub-district and village level health workers and monitors the implementation of the programme, actively supported by the district level Vector Borne Disease Unit (VBDU) in M&E and surveillance activities. The staff of the Primary Care Units (PCU), Sub-district Health Centres (SDHC), Community Health Posts (CHPs) and Community Primary Health Care Centres (CPHCC) implement various activities of the programme such as MDA, M & E and surveillance and Morbidity Management and Disability Prevention (MMDP).

Delineation of endemicity {#Sec5}
-------------------------

As a result of control measures and socio-economic improvement, LF distribution become very focal and restricted to some sub-villages. In the year 2001, when preparations started for establishing the NPELF, all historical data on prevalence up to sub-village level including environmental conditions of all the provinces were carefully examined and 11 provinces were declared endemic for LF.

MDA as the major intervention for the LF elimination programme {#Sec6}
--------------------------------------------------------------

The MDA programme was launched in the year 2002 and was implemented annually in consecutive years from 2002 to 2006 in endemic implemented units (IUs) of 11 provinces involving a total of 357 IUs with a total population of 124 496 (year 2002). As recommended by the WHO, DEC and Albendazole (ALB), were used in the MDA programme \[[@CR8]\]. The dosage used was DEC at 6 mg/kg body weight plus a fixed dose of 400 mg ALB for each individual.

The quantities of medicines required for MDA for each IU was estimated annually. DEC tablets were procured from the local pharmaceutical companies by the MoPH and ALB received as donation from the donor pharmaceutical company, GlaxoSmithKline (GSK), through WHO South-east Asia Regional Office (SEARO). DEC tablet formulations included 50 mg and 300 mg, and ALB 400 mg. The quality of local DEC was assessed per the MoPH Food and Drug Administration (FDA) guidelines and found to meet the standards. Medicines were always procured at least 2--3 months in advance of the MDA activity to avoid delays. The medicines from BVBD were sent to PHO, from where they were sent to district, sub-district and health centers where it was repacked as single doses into small plastic sachets (a plastic sachet contained medicines required for one person) according to requirement for each IU. The repacked sachets for each IU were then sent to Village Health Volunteer (VHV), who implements various health programmes of the government at community level.

### MDA: delivery channel {#Sec7}

MDA was implemented every year in the month of April where 1 week in the month was designated as 'Filaria week' to actively implement the MDA programme. While some IUs completed MDA in 1 week, others required 2--3 weeks and the reports are completed in 4 to 8 weeks' time. Depending upon population size, the number of VHVs employed per village mostly ranged from 5 to 10. Each volunteer was allocated a target of about 10--15 households. The health officers of the health centers supervised the drug distribution activity. The respective PHO closely monitored the drug distribution activity in each province. The policy of the programme is directly observed treatment where in every village the volunteer visited each household, provided the drug to each member and ensured treatment in his/her presence. Drugs were mostly distributed in the evening/night, between 18:00 and 21:00 h, and, as much as possible, treatment was given post-dinner to reduce the occurrence and severity of adverse events. In some provinces, drugs were administered also in some common places such as temples, community centres, leader's house and mosque.

### MDA: Eligible population {#Sec8}

Children \<2 years age and pregnant women and people with chronic disease conditions were excluded from treatment. All other groups were included for MDA and treatment. Drug dosage for each individual was determined based on age and weight and the medicines were given according to the age of the individuals.

### Training cascade {#Sec9}

Prior to launching the programme in 2002, the Division of LF provided training to the trainers, who included provincial level staff from the VBDC and PHO. Subsequently, they trained the staff at district level from the VBDU and DHO and health centers. The latter trained the VHV. Training was conducted at health centers for 1 day. The training was conducted every year, prior to the filaria week. Training focused on the objectives and goals of the LF elimination programme, transmission of LF and MDA programme that include details on medicines, dosage, exclusion and inclusion criteria, adverse events, social mobilization and microplanning.

### Social mobilization {#Sec10}

The LF elimination programme and MDA implementation was supported by an Information, Education and Communication campaign across all IUs in most of the target village emphasizing the importance of participating in MDA. In more endemic provinces, big events were held during the first or second day of Filaria Week with participation of Director-General of the DDC and other senior officers and officials from PHO.

### Severe adverse events reporting and response {#Sec11}

The VHV monitored the occurrence of adverse events (AEs) in the treated population drug distribution. Adverse events were reported by a health personnel through a national AE form that recorded any unusual symptoms for 2--3 days after ingestion of the drug. VHVs were also trained to inform those receiving the drug to report to the nearest health center if they had unusual symptoms. If those symptoms required further treatment, they were referred to the nearest district or provincial health facility for further management. However, throughout the MDA implementation period, the incidence of adverse events was negligible and there were no reports of any severe adverse event.

### Recording and reporting {#Sec12}

Structured household MDA forms were distributed at sub-district levels to VHV. The forms included all details of IU and name, age and gender columns for each household member and year-wise columns for drug distribution details. All the data were computerized in the Division of LF and hard copies retained. The denominator used for the calculation of epidemiological and national treatment coverage was the data from household forms which included the entire population of all age-groups which was updated every year.

This article describes the intensive MDA coverage in Thailand over the years from 2002 to 2011 and the subsequent impact of MDA through extensive monitoring and evaluation surveys -- mainly through the Stop-MDA surveys and transmission assessment surveys. We also describe additional interventions through a LF chronic disease survey and outcomes of the LF survey among cats and LF surveillance among migrants that collectively enabled the validation of LF elimination in 2017. We also discuss briefly Thailand's post LF elimination plans.

Methods {#Sec13}
=======

Monitoring and evaluation (M&E) surveys {#Sec14}
---------------------------------------

The programme undertook very extensive M&E surveys in three *W. bancrofti* endemic provinces with large number of IUs (Mae Hong Son, Tak and Kanchanaburi) and all the four *B. malayi* endemic provinces (Surat Thani, Krabi, Nakhon Si Thammarat and Narathiwat) to critically assess the impact of MDA. These seven provinces account for 346 of 357 IUs. The M&E consisted of (i) baseline mf surveys in 2001; (ii) interim (sentinel site or spot-check site) throughout the intervention period which consisted of mf surveys and antigenaemia surveys in *W. bancrofti* endemic provinces, and mf and antibody surveys in *B. malayi* endemic provinces (2002--2005 in ten provinces) and in Narathiwat (2002--2011); (iii) Stop-MDA surveys in 2006 in 11 provinces, and (iv) Transmission Assessment Surveys (TAS) over 2012--2017. Figure [3](#Fig3){ref-type="fig"} summarizes the timelines of these surveys.Fig. 3Timeline of key National Programme to Eliminate Lymphatic Filariasis activities in Thailand: 2001--2017

### The baseline surveys (2001) {#Sec15}

These were assessments of mf using thick blood smear examination performed during between 20:00 h and 24:00 h in *W. bancrofti* endemic IUs and *B. malayi* endemic IUs in Narathiwat, or daytime in *B. malayi* endemic provinces of Krabi, Surat Thani and Nakhon Si Thammarat. Base-line data were collected in a total of 169 IUs. The blood smears were stained with Giemsa and examined at VBDC or VBDU. In other IUs, data from surveys done prior to 2001 were analysed and areas with mf prevalence of more than 1% or where there was abundance of vector breeding sites, were included as LF endemic.

### The interim surveys (2002--2011) {#Sec16}

Interim surveys were done every year during 2002--2011, covering each year a proportion of IUs of the eleven endemic LF provinces. Mf prevalence (%), antigen prevalence (%) and antibody prevalence (%) were used as M&E indicators.

### Stop-MDA surveys (2006) {#Sec17}

It has been envisaged and showed that five rounds of effective MDA are likely to interrupt transmission of LF \[[@CR9]\]. The surveys to stop MDA consisted of two components: (i) Assessment of antigenaemia or microfilaraemia in populations where surveys were conducted in the population age-groups of \> 6 years of age. (ii) Assessment of antigenaemia in children of ≤6 years. Immunochromatographic test (ICT) test kits were used to detect *W. bancrofti* infection and mf blood smears for *B*. *malayi*,

### Stop-MDA surveys in Narathiwat (2011) {#Sec18}

In Narathiwat, where additional rounds of MDA over 2006--2012 were conducted, Stop-MDA surveys were done in 2011 and used a TAS methodology sampling children ≤6 years of age in 87 IUs. FilariaDIAG RAPID (an ELISA IgG4 test developed jointly by Mahidol and Chiang Mai hospital, Thailand) \[[@CR10], [@CR11]\]. In brugian endemic provinces, antibody assessment was introduced as soon as Brugia rapid test (BR) were available for the programme.

### Additional surveys (2007--2011) {#Sec19}

With encouraging results from Stop-MDA surveys in 2006 from the ten LF endemic provinces (excluding Narathiwat province), the programme focussed on child surveys in order to detect ongoing transmission, if any, and initiate remedial measures. These child surveys continued through 2007--2011 in ten of the 11 provinces in all IUs. Antigen surveys using immunochromatographic test (ICT) were conducted in *W. bancrofti* endemic provinces (*n* = 7, 489 IUs) and antibody surveys were conducted in *B. malayi* endemic provinces (*n* = 3, 15 IUs).

### Transmission assessment surveys (TAS) (2012--2017) {#Sec20}

As per WHO recommendations, two rounds of TAS was conducted after more than 4 years cessation of MDA \[[@CR12]\]. TAS were school based, as the primary school enrolment rate was \> 75%. Prior to every TAS, the BVBD approached and explained the objectives of the survey and sought the support of The Basic Education Commission, Ministry of Education (MOE). The MOE informed all the schools to participate in the surveys. The TAS teams contacted the principals of the schools and briefed them about the surveys, and provided an information sheet to all the parents highlighting the purpose and objectives of the survey. The written consent of the parents was obtained for each child. Refusal to consent was reported to be very rare. Within each evaluation unit (EU), the schools were selected and sample size determined using Survey Sample Builder (<https://www.ntdsupport.org/resources/transmission-assessment-survey-sample-builder>).

The first surveillance, TAS-1 (2012--2013) was conducted in all IUs of 11 provinces which were regrouped into three EUs (EU-1, EU-2 and EU-3). In TAS-2 (2015), the survey was done only in Narathiwat province where the 87 IUs grouped in EU-3 were further reorganized to 3 separate EUs -- EU-3.1 (18 IUs), EU-3.2 (32 IUs) and EU-3.3 (37 IUs) to ensure robust evaluation of incidence of infection among children. In TAS-3 (2016--2017), all five EUs were surveyed. The impact indicator used in TAS was antigenaemia incidence and prevalence in *W. bancrofti* endemic areas and antibody incidence and prevalence in *B. malayi* endemic areas among pre-school, 1st and 2nd grade school students, most of who are in 6--7 year age-group. The antigenaemia prevalence was measured using ICT card tests during the TAS-1 and 2 and Filaria Test Strip (FTS) during TAS-3. The antibody prevalence was measured using the BR. Children showing positive result for antibody test done during the day time in *B. malayi* endemic areas, were blood tested also for mf during the night. All children with antigenaemia or antibody positive were treated with full course of DEC. DEC was given six monthly thereafter for two consecutive years. In *B. malayi* endemic provinces, if any antibody positive person was found with mf, a contact survey was undertaken. All members of about 15 households close to the mf positive household were blood tested for mf and if found to be positive, a full course of DEC was administered.

### LF chronic disease survey {#Sec21}

At the commencement of preparations for the MDA in 2001, the program initiated in parallel to epidemiological surveys, a LF chronic disease survey as part of its strategy for Morbidity Management and Disability Prevention (MMDP). The health workers of the health centers of the sub-district in LF endemic areas assessed the presence of patients affected with lymphoedema/elephantiasis or hydrocele during regular house visits and when blood surveys were conducted. A list of chronic disease patients was prepared for each health center in each province and updated every year. The health workers visited all the households with patients. They were trained to provide care as well as education to the patients and family members on leg hygiene and the patients were followed up for 2 months to support them in the practice of leg hygiene. The patients were given a MMDP kit that contained soap, cotton, bandage, anti-fungal ointment (Clotrimazole), gauze cloth, towel and anti-septic solution (Ipodine). Some patients were also provided with elastic stockings. Each patient was also given a booklet with pictures of MMDP steps. These kits were provided once to the patient with instructions that if an episode of acute dermatolymphangioadenitis (ADL) occurs, the patient could approach the nearest health facility to obtain supportive medication such as paracetamol for fever, ipodine for wound dressing, pressure bandage for lymph circulation etc. The patients were advised to consult doctors for the treatment of ADL attacks and any other related complications. Hydrocele surgeries are provided in provincial hospitals and although such cases are rare, necessary infrastructure, medicines and follow-up services to undertake hydrocele surgery are available in all the provincial hospitals.

Results {#Sec22}
=======

Delineation of endemicity {#Sec23}
-------------------------

Within the 11 provinces, 357 sub-villages, were declared endemic for LF and eligible for the MDA programme (see Table [1](#Tab1){ref-type="table"}). The total population of the 357 sub-villages in 2002 was 124 496. Although all 11 provinces are endemic, four of these provinces -- Mae Hong Son, Tak, Kanchanaburi and Narathiwat, accounted for 336 of 357 (94%) of endemic sub-villages. In the same 11 provinces, a total of 283 villages were excluded from MDA, as the mf and/or antigen prevalence was below threshold levels of 1.0 and 2.0% respectively. The sub-village administrative unit was designated as an IU. The average population of an IU was 349. Figure [4](#Fig4){ref-type="fig"} shows the 11 LF endemic provinces mapped by the causative vector species. All IUs in the following were endemic for *W. bancrofti* (seven provinces), transmitted by *Aedes niveus*; and *B. malayi* (4 provinces), transmitted by *Mansonia* species. The *W. bancrofti* endemic provinces are located in north and central Thailand, *B. malayi* endemic provinces are in south Thailand.Table 1Number of sub-villages identified as endemic in eleven lymphatic filariasis (LF) endemic provinces and population in 2002ProvinceNumber of sub-villages identified as LF endemicTotal population in identified sub-villages (2002)Mae Hong Son7611 257Chiang Mai2370Lamphun32436Tak12431 200Ratchaburi4787Kanchanaburi4919 179Ranong24405Surat Thani64073Nakhon Si Thammarat2710Krabi2672Narathiwat8749 407Total357124 496Fig. 4Delineation of Lf endemicity at the commencement of the National Programme to Eliminate Lymphatic Filariasis in Thailand, 2001

MDA as major intervention for LF elimination {#Sec24}
--------------------------------------------

The mean MDA coverage for the entire country from 2002 to 2011 was 90.5% (68 to 95.6%), Table [2](#Tab2){ref-type="table"}. Due to the unrest in the south of Thailand, only 15 out of 87 IUs in Narathiwat could be covered with MDA. Stop-MDA surveys were done in the 15 IUs and although *B*. *malayi* mf prevalence was 0.2%, a decision was made to continue with more rounds of MDA. In one endemic province, Narathiwat (87 IUs), MDA had to be extended until 2012 for a total of 11 rounds due to persistent infection.Table 2Summary of national mass drug administration coverage during 2002--2011YearNumber of IUs coveredGeographical coverage (%)Total population of IUsReported number of people treatedProgramme (drug) coverage (%)2002340100%124 496114 95592.3%2003344100%147 177131 34689.2%2004345100%152 111131 39386.4%200534198.0% (341/348)166 636144 25286.6%200630888.3% (308/349)166 647113 38068.0%20077591.5% (75/82)77 93561 77679.3%200887100%79 26775 67195.5%200987100%81 60177 84295.4%201087100%81 09876 70794.6%201187100%83 10579 21095.3%*IUs* Intervention units

### The baseline surveys (2001) {#Sec25}

Of the 169 surveyed IUs in 2001, 129 IUs showed \< 1.0% mf prevalence, the threshold level at which LF transmission is unlikely to sustain.

### The interim surveys (2002--2011) {#Sec26}

The MDA programme was launched in the year 2002 and was implemented annually in consecutive years from 2002 to 2006 in endemic IUs of 11 provinces involving a total of 357 IUs with a total population of 124 496 (year 2002). Interim surveys were done every year during 2002--2011 and results (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) suggest that, with the progress of MDA, by 2005, only one IU, in Tak province, showed \>2.5% antigen prevalence. Almost all IUs in *B. malayi* endemic provinces, except Narathiwat province, showed \<1.0% mf prevalence and by 2005, mf carriers had become rare. In Narathiwat, endemic for *B. malayi*, as most IUs showed prevalence of microfilaraemia consistently \>1.0% until 2005, the programme decided to continue MDA for few more years. A total of 11 rounds of MDA were implemented in this province (2002--2012). The continuous interim surveys in Narathiwat province subsequently showed that in 2006, 2008 and 2009, the highest mf prevalence recorded was only 0.8% in the community (population of all age-groups).Table 3Details of interim surveys done in provinces endemic for *Wuchereria bancrofti*ProvinceYearAge groupAntigen survey^a^Microfilaria (mf) surveyNumber of IUs surveyedTotal population in IUs surveyedTotal number of people tested in IUs surveyedNumber of IUs with positive resultTotal number of population in IUs where found positiveTotal number of people tested in IUs where found positivePositive caseHighest prevalence observed in IUs surveyed (range)Number of IUs surveyedTotal population in IUs surveyedTotal number of people tested in IUs surveyedNumber of IUs with positive resultTotal number of population in IUs where found positiveTotal number of people tested in IUs where found positivePositive caseHighest prevalence observed in IUs surveyed (range)Mae Hong Son2002All00--000001527242122250950992.4%(1.0--2.4%)2003All1424851733231824553.2% (0.8--3.2%)11845201.9%2004All1219091538000000--0000002005All3651403000008118275300000Chiang Mai2004All000000001977159000002005All164631000001124032600000Lamphun2003All0000000022985655000002004All0000000022072738000002005All1^b^9827500000198262300000Tak2002All2056944242290340832.6% (0.3--2.6%)145846000002003All26603447952194145610.4% (1.0--10.4%)625351840000002004All1324962786616711283136.7% (0.2--6.7%)3632382000002005All8^b^2386240133128410.4%11^b^3145235800000RatchaburiNo survey dataKanchanaburi2002All3814 4109311634972292282.2% (0.5--2.2%)000000002003All8299125231240164116.7%413421319000002004All8357526960000061152982000002005All124524543232725262.5% (2.2--2.5%)104197354600000RanongNo survey data*IUs*: Intervention units^a^Antigen assessment, which is more sensitive than mf assessment, could not be adopted in every survey due to immunochromatographic test (ICT) card supply constraints^b^These IUs used both ICT card & mf detectionTable 4Details of interim surveys done in provinces endemic for *Brugia malayi*ProvinceYearAge-group surveyedNumber of IUs surveyedTotal population in IUs surveyedTotal number of people tested in IUs surveyedNumber of IUs with positive resultTotal number of population in IUs where found positiveTotal number of people tested in IUs where found positiveNumber of positive casesHighest prevalence observed in IUs surveyed (range)Microfilaria (mf) surveysSurat Thani2002All425801447425801447510.0% (0.2--10.0%)2003All1587454000002004All1591475000002005All21585978163254920.4% (0--0.4%)Nakhon Si Thammarat2002All1613609000002003All2777757000002004All2879741174762420.3% (0--0.3%)2005All287367200000Krabi2002All1425403000002003All2653382000002004All2654420000002005All143136200000Narathiwat2002All2815 50111 791**23**13 12511 119843.5% (0.2--3.5%)2003All2518 87312 8521510 3727211321.6% (0.2--1.6%)2004All2014 0729239972814683181.1% (0.1--1.1%)2005All2418 37310 097**16**11 8726490331.6% (0.1--1.6%)2007All3428 55717 5121515 6708589192.1% (0.1--2.1%)2008All3529 72018 93153982229550.5% (0.2--0.5%)2009All2319 97514 000669584642130.5% (0.1--0.5%)*IUs* Intervention units

### Stop-MDA surveys (2006) {#Sec27}

Antigenaemia and mf prevalence in *W. bancrofti* endemic provinces among populations \> 6 years of age was 0% in all evaluated IUs with only 1 IU showing mf prevalence of 2.7% (Table [5](#Tab5){ref-type="table"}). In three of the *B. malayi* endemic provinces (excluding Narathiwat), mf prevalence among populations \> 6 years of age in 10 IUs surveyed was 0%. In Narathiwat, out of 15 IUs surveyed, nine mf positive cases were detected in seven IUs with the highest mf prevalence of 0.8% (range: 0.1--0.8%). Assessment of antigenaemia and mf in children of ≤6 years showed that no child was found positive for antigen in any *W. bancrofti* IU in any province, and no child was found positive for mf in *B. malayi* in the three endemic provinces. The Stop-MDA surveys suggested that by 2006, transmission of LF and incidence of new infections had become very rare in the ten LF endemic provinces.Table 5Stop mass drug administration (MDA) surveysAntigen detectionFilarial parasiteNumber of provincesTotal number of IUsNumber of IUs surveyedTest usedResultStop MDA survey, 2006 \>  6 years of age*Wuchereria bancrofti*520620ICT206 IUs: 0%25426mf1 IU: \>  2.7%*Brugia malayi*49725mf7 IUs: 0.3% ^a^ ≤ 6 years of age*W. bancrofti*7260232ICT0%*B. malayi*49724mf0%Stop MDA survey -- Narathiwat province, 2011 ≤ 6 years of age*B. malayi*18787ELISA^b^71 IUs: 0%3 IUs: \<  2%^c^13 IUs: \>  2%^c^*ICT* Immunochromatographic test, *IUs* Intervention units, *Mf* Microfilaria^a^ *Out of 25 IUs, 15 IUs surveyed were in Narathiwat province. Nine mf positive cases were detected in seven IUs in Narathiwat province with, highest mf prevalence of 0.8% (0.1--0.8%)*^b^*FilariaDIAG RAPID (an ELISA IgG4test developed jointly by Mahidol and Chiang Mai hospital, Thailand)*. *In Brugia endemic provinces, antibody assessment was introduced as soon as Brugia rapid test were available for the programme*^c^ *Antibodies detected in 16 IUs among 26 children \[Antibody rate: 33.3% (11.0--33.3%) who were subsequently tested for mf of whom seven were positive \[mf positivity rate: 4.2% (0.4--4.2%). ELISA test was used during the day time for children. Positive ELISA cases were subsequently tested for mf during the night*

### Stop-MDA surveys in Narathiwat (2011) {#Sec28}

Following the last round of MDA in Narathiwat, a Stop-MDA survey was done in 2011. Of the 87 IUs surveyed, antibodies were detected among 26 children in 16 IUs who were subsequently tested for mf of whom seven were positive, and the mf positivity rate ranged from 0.4 to 4.2%.

### Additional surveys (2007--2011) {#Sec29}

Child surveys continued through 2007--2011 in ten of the 11 provinces in all IUs. None of the sampled children was found positive either for antigen or antibody among a number of IUs surveyed during different years, indicating near total interruption of transmission.

### Transmission assessment surveys (TAS) (2012--2017) {#Sec30}

The coverage and results of both TAS-1 to TAS-3 are shown in Table [6](#Tab6){ref-type="table"}. In TAS-1 (2012--2013), the number of children positive for antigen or antibody was much lower than critical cut off value in both EU-1 and EU-2, and no child was found to be mf positive in EU-2 which clearly indicated that transmission was completely interrupted in both the EUs. In Narathiwat province (EU-3) which had historically higher prevalence rates and required more MDAs, TAS-1 sampled 1018 children against the target of 1356 in all the 87 IUs. The under sampling was due to some unrest incidents in the province involving schools. Antibody prevalence was 0.7% with seven children positive, against the critical cut off value of 16. Of the seven antibody positive children, two were mf positive. The results suggest that LF transmission was well below threshold levels in Narathiwat by 2013. In TAS-2 (2015), EU-3 was reorganized into three EUs and the number of children found positive for antibody was either equal or below the critical cut off value signifying transmission below threshold level. Two of the 11 antibody positive children showed mf in the blood. The same EU grouping was continued for TAS-3 (2016--2017) in all 11 provinces (Table [6](#Tab6){ref-type="table"}). None of the tested children were found positive except for EU 3.3, where four of the 530 children were tested positive for antibody, against the critical cut off value of six. This indicated that transmission was totally interrupted in all five EUs. In all the three TAS, contact screening of mf positive children were done among household members of about 15 households around each of the mf positive child, and none of the household members were found positive.Table 6Transmission Assessment Surveys (TAS) 2012--2017: Coverage and resultsYearNumber of provincesNumber of EUsNumber of IUsNumber of children testedSpecies^a^/TestNumber children positive for antigen or antibody ^b^/ critical cut off valueNumber of mf positive children ^c^Contact survey result2012--10EU-12601786WB/Ag0 /110--2013 (TAS-1)EU-210129BM/Ab1 / 20--EU-3871018BM/Ab7/162Negative2015 (TAS-2)1EU-3.118284BM/Ab2 / 30--EU-3.232506BM/Ab3 / 60--EU-3.337506BM/Ab6 / 62Negative2016--2017 (TAS-3)11EU-12602233WB/Ag ^d^0 /110--EU-210144BM/Ab0 / 20--EU-3.118284BM/Ab0 / 30--EU-3.232506BM/Ab0 / 60--EU-3.337530BM/Ab4 / 63Negative*EUs* Evaluation units; IUs: Intervention units^a^ *WB: Wuchereria bancrofti; BM: Brugia malayi*^b^ *Antigen (Ag) with immunochromatographic test (ICT); Antibody (Ab) with Brugia Rapid test*^c^ *Among Ag or Ab positive children*^d^ *Filaria Test Strip (FTS) was used instead of ICT*

### LF chronic disease survey {#Sec31}

The number of lymphoedema/elephantiasis patients detected during different years in Thailand is shown in Table [7](#Tab7){ref-type="table"}. An update registry maintained at BVBD as of April 2017 showed a total of 99 patients followed-up under 34 health centers, of which, a total of 69 patients (70%) were under the care of 14 health centres in just one province of Nakhon Si Thammarat.Table 7Number of lymphoedema/elephantiasis patients detected during different fiscal years (FY) in ThailandProvinceFY 2001FY 2005FY 2006FY 2007FY 2014FY 2015FY 2016Chumphon1010107663Surat Thani3125251813139Nakhon Si Thamrat1811811811621258669Krabi1000111Phangnga2331000Phatthalung1313139661Pattani1726261917179Narathiwat2933332917178Total284291291245185146100

Special issues {#Sec32}
--------------

### LF in cats {#Sec33}

As early as the late 1980s, cat surveys documented *B. malayi* and *B. pahangi* infection among domestic cats in all four *B*. *malayi* endemic provinces of Surat Thani, Nakhon Si Thamarat, Krabi and Narathiwat. LF infection was not found in other animals such as dogs and monkeys \[[@CR5], [@CR13]\]. To interrupt zoonotic transmission, beginning in 2003, active surveillance of cats in areas with \> 1.0% mf rate among cats was done along with mass treatment of cats with ivermection given subcutaneously. In addition, in every area, all the cats found with LF infection were treated with ivermectin annually. As a result of this intensive treatment, the mf prevalence among cats declined from 8.1% in 1995 to as low as 0.8% in 2015. Post elimination surveillance in Narathiwat and other *B. malayi* endemic provinces will continue to perform cat surveys and treatment along with ongoing surveillance in human population to prevent possible zoonotic transmission of LF in Narathiwat.

### LF surveillance among migrants {#Sec34}

Attapeu province in Lao Peoples Democratic Republic is endemic for LF but it shares no immediate geographic border or significant population movement with Thailand \[[@CR14]\]. The Preah Vihear province of Cambodia, which was endemic for LF, borders Thailand but has since achieved validation of elimination of LF in the year 2016. Although four border states of Kedah, Kelantan, Perak and Perlis in Malaysia border the provinces of Narathiwat, Satun, Songkhla and Yala, these states had achived LF elimination with only Perak receiving 5--7 rounds of MDA and passed TAS-1 by 2016 \[[@CR15]\].

However, Thailand shares a very long border with Myanmar, several provinces of which are endemic for LF caused by *W. bancrofti* and transmitted by *Culex quinquefasciatus*. Although there has been some debate on human-vector combinations on the risk of *W. bancrofti* transmission across the Thai-Myanmar borders \[[@CR16], [@CR17]\], current data/information thus far is not sufficient to understand the vulnerabilities on how contagious is the parasite in such complex epidemiological settings as well as the receptivity of the vector in different ecological settings along the borders \[[@CR18]\]. Numerous studies among Myanmar migrants \[[@CR19]--[@CR22]\] in Thailand, prior to intensive MDA campaigns in Myanmar, documented higher prevalence of antigens and antifilarial antibodies among Myanmar immigrants \[[@CR23]\]. Since 2001, the Thai MoPH set up the migrant health insurance scheme for all migrants (documented and undocumented) who are not covered by social health insurance, allowing mandatory health screening (during the first entry and subsequent yearly renewal of the residence permit) \[[@CR24]\] which includes testing for bancroftian mf (mf challenge test with DEC) which is done at all district hospitals and for which a full course of treatment (single dose of DEC + ALB) is offered if found to be positive.

In addition, in a number of provinces (average: 19, range: 13--25) where there were significant number of migrant workers registered, sentinel site surveillance for mf was done annually between 1996 and 2001 with a total of 204 108 persons tested with a blood film for mf yielding an average positivity rate of 0.7% (range: 0.2--2.2%) over the same period \[[@CR25]\]. With the commencement of the NPELF, the annual surveillance of migrants was focused on seven provinces over 2002--2017 with 23 477 persons tested for LF antigen using ICT test cards, showing a positivity rate of 0.7% (range: 0.1--2.7%) over the same period. Where antigen positivity was detected among migrants in these areas, the Thai populations residing in close proximity were also concurrently tested over the same period (average 2616) with zero positivity rates. In addition, the local health facilities are encouraged to treat the immigrant population regardless of legal status. Both measures, the MDAs conducted in Myanmar \[[@CR26]\] and the screening and treatment of migrants in Thailand \[[@CR27]--[@CR29]\], were probable contributors to the decline in the number of LF cases detected in Thailand among Myanmar migrants.

Discussion {#Sec35}
==========

Elimination of LF as a public health problem is defined as reduction in measurable prevalence of infection in endemic areas below a target threshold at which further transmission is considered unlikely even in the absence of MDA \[[@CR30]\]. These target thresholds are measured during TAS. However, a programme must first achieve \<1% microfilaraemia or \< 2% antigenaemia among populations aged older than 5 years in sentinel and spot-check sites considered high-risk. Then, all endemic areas should pass TAS (the number of positive children is less than the critical cut-off value indicating infection is below elimination thresholds) and stop MDA. Infection must be maintained below these levels for at least 4 years after MDA has stopped.

Role of government {#Sec36}
------------------

Since the establishment of the Division of Lymphatic Filariasis in 1961 under the Department of Health of the Royal Thai Government ensured that resources were allocated for national surveys to identify the endemic areas, followed by integrated vector control efforts, continuous entomological and parasitological surveillance efforts, and repeated annual rounds of high coverage MDAs among at-risk groups. With the establishment of the universal health coverage (UHC) scheme in 2001 and subsequently migrant health insurance schemes, the provision of free morbidity management and disability prevention services were extended to the sub-district Tambon Health Promotion Hospital and for both registered and unregistered migrants. The Regional LF offices (five regions) established in the in the 1970s were instrumental in overseeing case finding, treatment and entomological surveys under LF control program. The Thai Royal Filaria Project established the Phikulthong Royal Development Study Center in Narathiwat province provided all necessary support with infrastructure and required personnel for LF control, and subsequently elimination efforts in Narathiwat Province.

Partnerships {#Sec37}
------------

Thailand has partnered with WHO and national universities such as Mahidol University especially in the early surveys undertaken in the 1950s to the 1960s. ALB was provided by GlaxoSmithKline through the WHO donation program. DEC (50 and 300 mg) was procured by the program from a local pharmaceutical manufacturer. Eisai Co., Ltd. provided on request in 2015, for 100 mg tablet of DEC to be used in children. WHO SEARO assisted with the procurement of ICT, FTS and BR for TAS as well as training programmes for LF patients. Excellent support was provided by the Ministry of Education through its Basic Education Commission, for TAS in school children.

Validation {#Sec38}
----------

Based on the MDA coverage data, TAS results and the established MMDP services, a country dossier was prepared under the guidance of the Regional Programme Review Group (RPRG). The dossier documented sufficient evidence that Thailand has met the established criteria to validate elimination of LF as a public health problem. An independent Regional Dossier Review Group convened by WHO reviewed the dossier in mid-2017 and endorsed that the elimination criteria was met. Based on this evidence, WHO validated and formally acknowledged that the Kingdom of Thailand has eliminated LF as a public health problem in September 2017.

Post validation surveillance {#Sec39}
----------------------------

The RPRG in its review recommended that Thailand continue post-MDA activities monitoring for infection in migrant population and zoonotic hosts of *B. malayi*. It also recommended continuing soil-transmitted helminthiases (STH) control activities in the areas at risk. A health facility survey is planned to be conducted every 2 years from 2017 in all areas with LF patients. The quality of services provided to the patients will be assessed through the following methods: (1) availability of medicines; (2) assessment of the number of patients with ADL and lymphoedema visiting the health facility; and (3) interview with health personnel on the treatment provided to patients and (4) interview with patients to assess their opinion on services provided and improvement in quality of life. The data collected by visiting the health centers will be analyzed and corrective steps, if necessary, will be taken to improve the services. Targeted surveillance will continue every 2 years in all previous ten LF endemic provinces with a coverage of 10% of total IUs in each province. All populations in these IUs will be blood surveyed. In Narathiwat province this will be done annually in 10% of total IU. Vector surveys will be conducted in 1% of total IUs in each province. In migrants, both routine health screening for migrant workers and blood spot checks annually and mosquito surveys will continue in communities in the ten LF endemic provinces depending where there are high influx or movement of migrant workers. Additionally, in Narathiwat province, surveillance among cats will be conducted periodically.

Conclusions {#Sec40}
===========

From the baseline survey in 2001, the LF elimination programme in Thailand represents a typical post-control low endemic situation (i.e. a few decades of mf surveys and test and treatment strategy prior to commencing a LF elimination programme). The approach of the programme in affected provinces to adopt a sub-village as the IU also ensured a smaller population size and thus achieve better social mobilization efforts and compliance in taking annual doses of the medication even though they showed no symptom of disease. The interim surveys throughout the MDA period showed that mf and antigen prevalence was restricted to only a few IUs falling below threshold level in a significant number of IUs (except in Narathiwat province) by 2005. In highly endemic province of Narathiwat, IUs were reorganized to three separate EUs during TAS to ensure robust evaluation of incidence of infection among children. Sustained commitment by the government and dedicated health staff on the ground throughout the elimination phase, not only ensured the NPELF objectives were met finally in 2017 but also ensuring that high quality of care be continued for chronic LF patients. Along with post validation surveillance efforts every 2 years, the program will continue its LF surveillance efforts especially among migrant populations along provinces bordering Myanmar. The Phikulthong Royal Development Study Center in Narathiwat will continue monitoring for zoonotic LF transmission while focusing on STH and Leprosy control as well.
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